J&J Pharma R&D Taps Entelos for In Silico Studies of Type-2 Diabetes Therapies

Dec 19, 2007

NEW YORK (GenomeWeb News) - Entelos said today that has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development to use its predictive computer models of human physiology to study new therapies for type-2 diabetes.

Under the agreement, Entelos will use its in silico “virtual patients” to discover and evaluate therapies for the disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Johnson, Brexit, and Science

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

ICE Expands DNA Testing Sites

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

PNAS Papers Explore Neurogenesis Exosomes, More

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Rolling It Back

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.

Menu